Released September 25, 2020 | new delhi
en
The Council of Scientific & Industrial Research (CSIR), India's premier research organization, and Mylan Laboratories Limited, the India-based subsidiary of global pharma giant Mylan, on Thursday announced a partnership to address unmet patient needs amidst the evolving COVID-19 pandemic.
Under the partnership, CSIR's constituent laboratory--Indian Institute of Chemical Technology (IICT)--and Mylan will collaborate to identify potential therapies for COVID-19. IICT has achieved many breakthroughs in the past months in process development of major drugs used in the treatment of COVID-19.
"A series of clinical trials will be conducted towards new and innovative solutions to manage COVID-19 pandemic in India as part of this collaboration. The first of the clinical trial to be rolled out is a multiple arm phase 3 study that will be conducted in adult patients with mild to moderate COVID-19 at risk of complications," said a CSIR in a statement.
See map below to locate Mylan's pharmaceutical plants in India.
Under the partnership, CSIR's constituent laboratory--Indian Institute of Chemical Technology (IICT)--and Mylan will collaborate to identify potential therapies for COVID-19. IICT has achieved many breakthroughs in the past months in process development of major drugs used in the treatment of COVID-19.
"A series of clinical trials will be conducted towards new and innovative solutions to manage COVID-19 pandemic in India as part of this collaboration. The first of the clinical trial to be rolled out is a multiple arm phase 3 study that will be conducted in adult patients with mild to moderate COVID-19 at risk of complications," said a CSIR in a statement.
See map below to locate Mylan's pharmaceutical plants in India.
